CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1− mantle cell lymphoma

Author:

Martín-Garcia David12ORCID,Navarro Alba12,Valdés-Mas Rafael3,Clot Guillem12ORCID,Gutiérrez-Abril Jesús3,Prieto Miriam12,Ribera-Cortada Inmaculada4,Woroniecka Renata5,Rymkiewicz Grzegorz6,Bens Susanne78,de Leval Laurence9ORCID,Rosenwald Andreas1011,Ferry Judith A.12,Hsi Eric D.13,Fu Kai1415,Delabie Jan1617ORCID,Weisenburger Dennis18,de Jong Daphne19,Climent Fina20,O’Connor Sheila J.21,Swerdlow Steven H.22,Torrents David2324ORCID,Beltran Sergi25ORCID,Espinet Blanca2627,González-Farré Blanca228,Veloza Luis28,Costa Dolors228,Matutes Estella28,Siebert Reiner78,Ott German2930,Quintanilla-Martinez Leticia31ORCID,Jaffe Elaine S.32ORCID,López-Otín Carlos23,Salaverria Itziar12ORCID,Puente Xose S.23ORCID,Campo Elias122833ORCID,Beà Sílvia12ORCID

Affiliation:

1. Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain;

2. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain;

3. Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain;

4. Hospital Nostra Senyora de Meritxell, Escaldes-Engordany, Andorra;

5. Cytogenetic Laboratory and

6. Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie Institute–Oncology Center, Warsaw, Poland;

7. Institute of Human Genetics, Ulm University Medical Center, Ulm University, Ulm, Germany;

8. Institute of Human Genetics, Christian Albrechts University Kiel/University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany;

9. Institut de Pathologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland;

10. Institute of Pathology and

11. Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany;

12. Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA;

13. Cleveland Clinic Foundation, Cleveland, OH;

14. Department of Pathology and Microbiology and

15. Division of Oncology and Hematology, Department of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, NE;

16. Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada;

17. Oslo University Hospital, Oslo, Norway;

18. Department of Pathology, City of Hope National Medical Center, Duarte, CA;

19. VU University Medical Center, Amsterdam, The Netherlands;

20. Hospital Universitari de Bellvitge–Institut d’Investigació Biomédica de Bellvitge (IDIBELL), L’Hospitalet de Llobregat, Spain;

21. Haematological Malignancy Diagnostic Service (HMDS) Laboratory, St. James’s Institute of Oncology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom;

22. Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, PA;

23. Joint Barcelona Supercomputing Center (BSC)–Centre for Genomic Regulation (CRG)–Institute for Research in Biomedicine (IRB) Research Programme in Computational Biology, Barcelona, Spain;

24. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain;

25. Centre Nacional d’Anàlisi Genòmica (CNAG)–CRG, Barcelona, Spain;

26. Laboratori de Citogenètica Molecular, Servei de Patologia, Hospital del Mar, Barcelona, Spain;

27. Grup de Recerca Translacional en Neoplàsies Hematològiques, Cancer Research Programme, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM)–Hospital del Mar, Barcelona, Spain;

28. Hematopathology Section, Hospital Clínic de Barcelona, Barcelona, Spain;

29. Department of Clinical Pathology and

30. Dr Margarete “Fischer Bosch Institute” of Clinical Pharmacology, Robert Bosch Hospital, Stuttgart, Germany;

31. Institute of Pathology, Eberhard Karls University of Tübingen, Tübingen, Germany;

32. Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; and

33. Department of Anatomic Pathology, University of Barcelona, Barcelona, Spain

Abstract

Abstract Mantle cell lymphoma (MCL) is characterized by the t(11;14)(q13;q32) translocation resulting in overexpression of cyclin D1. However, a small subset of cyclin D1− MCL has been recognized, and approximately one-half of them harbor CCND2 translocations while the primary event in cyclin D1−/D2− MCL remains elusive. To identify other potential mechanisms driving MCL pathogenesis, we investigated 56 cyclin D1−/SOX11+ MCL by fluorescence in situ hybridization (FISH), whole-genome/exome sequencing, and gene-expression and copy-number arrays. FISH with break-apart probes identified CCND2 rearrangements in 39 cases (70%) but not CCND3 rearrangements. We analyzed 3 of these negative cases by whole-genome/exome sequencing and identified IGK (n = 2) and IGL (n = 1) enhancer hijackings near CCND3 that were associated with cyclin D3 overexpression. By specific FISH probes, including the IGK enhancer region, we detected 10 additional cryptic IGK juxtapositions to CCND3 (6 cases) and CCND2 (4 cases) in MCL that overexpressed, respectively, these cyclins. A minor subset of 4 cyclin D1− MCL cases lacked cyclin D rearrangements and showed upregulation of CCNE1 and CCNE2. These cases had blastoid morphology, high genomic complexity, and CDKN2A and RB1 deletions. Both genomic and gene-expression profiles of cyclin D1− MCL cases were indistinguishable from cyclin D1+ MCL. In conclusion, virtually all cyclin D1− MCLs carry CCND2/CCND3 rearrangements with immunoglobulin genes, including a novel IGK/L enhancer hijacking mechanism. A subset of cyclin D1−/D2−/D3− MCL with aggressive features has cyclin E dysregulation. Specific FISH probes may allow the molecular identification and diagnosis of cyclin D1− MCL.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 71 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3